Welcome to our dedicated page for Bioxytran news (Ticker: BIXT), a resource for investors and traders seeking the latest updates and insights on Bioxytran stock.
Bioxytran, Inc. develops carbohydrate-based biotechnology programs focused on hypoxia, viral diseases, inflammation, metabolic health, and degenerative disease. News about BIXT commonly centers on ProLectin-M, its investigational oral antiviral candidate, including clinical study results, dose-optimization work, viral-clearance data, and regulatory-discussion updates for later-stage development.
Company updates also cover Bioxytran’s galectin-targeting platform, research collaborations involving polysaccharide and oligosaccharide interactions, and applications such as PHM23 in avian influenza research. Commercial news includes A-SUQAR®, a chewable dietary supplement containing a proprietary partially hydrolyzed guar gum formulation, along with distribution agreements and private-placement financing used for working capital and development programs.
Bioxytran (OTCQB:BIXT) announced that CEO David Platt, Ph.D. will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on February 5, 2026. The presentation includes a fireside Q&A and will overview corporate strategy, pipeline focus, and previously disclosed clinical and regulatory progress.
A video webcast will be available after the event and archived on the company website and Channelchek.com for 90 days.
Bioxytran (OTCQB: BIXT) executed a Sponsored Research Agreement with the University of Minnesota to study polysaccharide and oligosaccharide interactions using advanced nuclear magnetic resonance (NMR) methods under Dr. Kevin Mayo. The program runs through early 2027 with milestones, funding for personnel and NMR access, and university IP ownership with broad data rights for Bioxytran.
The collaboration aims to deepen structural understanding of carbohydrate-binding interactions to inform Bioxytran's therapeutic and diagnostic R&D pathways.
Bioxytran (OTCQB:BIXT) issued a corporate update on January 29, 2026 highlighting progress across its ProLectin‑M antiviral program, an active U.S. FDA IND, dose-optimization completion, and work on an oxygen-transport platform including a joint venture with the Heme Foundation.
The release reiterates prior milestones: completion of a randomized, double-blind, placebo-controlled ProLectin‑M trial in October 2025, dose-optimization work in May 2025, a July 2024 JV for a universal oxygen carrier, and a January 2025 cancer-focused galectin‑3 preprint.
Bioxytran (OTCQB:BIXT) announced on Nov 13, 2025 that Independent Research initiated coverage of the stock and published a report highlighting clinical and corporate updates.
Key clinical data for lead candidate ProLectin-M: 88% viral clearance by day 3 and 100% by day 7 in mild-to-moderate COVID-19, with no serious adverse events reported. The drug targets the galectin fold and is positioned as a potential broad-spectrum antiviral.
Pipeline focus includes ambulatory stroke candidate BXT-25 aimed at expanding the 3-hour treatment window. The report flags funding as the primary risk and notes >50% insider ownership and active pursuit of strategic partnerships.
Bioxytran (OTCQB: BIXT) announced on October 29, 2025 the completion of a randomized, double-blind, placebo-controlled dose-optimization trial for its oral broad-spectrum antiviral candidate ProLectin-M. The company says prior Phase 2 results showed treated participants reached undetectable PCR viral levels in less than one week. Data from the new trial will be used to inform a phase 3 trial design for CDSCO and will be submitted to the FDA at the agency's request. Bioxytran expects to compile detailed safety and efficacy endpoints for peer-reviewed publication and plans to submit full results in the coming weeks.
Bioxytran (OTCQB: BIXT) announced a significant scientific advancement with the publication of a groundbreaking book by Prof. Avraham Mayevsky on tissue oxygenation and mitochondrial function. The research highlights the limitations of current peripheral oxygen measurements and introduces a paradigm shift towards tissue-specific oxygenation monitoring.
The company's MDX Viewer technology, combined with their Universal Oxygen Carrier (UOC) and BXT-25 development programs, aims to revolutionize treatment approaches for conditions like stroke and Alzheimer's disease. The technology will serve as a crucial biomarker in upcoming BXT-25 clinical trials, potentially transforming how oxygen delivery is measured and managed in critical conditions.
Bioxytran (OTCQB: BIXT) has announced significant progress in developing ProLectin-M, its broad-spectrum antiviral drug. The company has completed dosing in its dose optimization clinical trial, marking a crucial milestone in the drug's development.
ProLectin-M targets galectin fold on viral spike proteins and has shown impressive clinical results: 100% response rate (negative PCR tests) by day 7 and 88% response rate by day 3 in double-blinded placebo-controlled trials. The drug has demonstrated effectiveness against SARS-CoV-2, influenza, and RSV, with no viral rebounds during the 14-day observation period.
The drug's development, supported by an active FDA IND application, utilizes proprietary linear complex carbohydrate structures designed with nuclear magnetic resonance and AI to neutralize viral infectiousness.